SPRO
NASDAQSpero Therapeutics Inc.
Price$2.19-0.28 (-11.34%)
2026-03-182026-06-22
News · 26 weeks21-50%
2025-12-282026-06-21
Mix1590d
- SEC Filings8(53%)
- Other4(27%)
- Earnings1(7%)
- Insider1(7%)
- Leadership1(7%)
Latest news
25 items- SECSpero Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the US Approval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatment1 More than 3 million cases of cUTIs are treated annually in the US2 with up to a third of patients impacted by resistant infections3 GSK plc (LSE/NYSE:GSK) and Spero Therapeutics (NASDAQ:SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and o
- PRUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)First and only oral carbapenem antibiotic approved in the USApproval based on PIVOT-PO trial demonstrating non-inferiority compared to intravenous treatmentiMore than 3 million cases of cUTIs are treated annually in the US with a third of patients impacted by resistant infectionsii,iii CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) and GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative or
- PRCompass Pathways Elects Kathleen Tregoning to Board of DirectorsCompass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. "With two successful Phase 3 trials meeting the primary endpoint, a
- SECSEC Form 10-Q filed by Spero Therapeutics Inc.10-Q - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business UpdateNew Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026Spero maintains its cash runway guidance into 2028 CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we pre
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- INSIDEROfficer Rajavelu Esther sold $63,352 worth of shares (25,240 units at $2.51), decreasing direct ownership by 2% to 986,851 units (SEC Form 4) to cover taxes4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- PRSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases w
- SECSEC Form DEFA14A filed by Spero Therapeutics Inc.DEFA14A - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form DEF 14A filed by Spero Therapeutics Inc.DEF 14A - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form PRE 14A filed by Spero Therapeutics Inc.PRE 14A - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form 10-K filed by Spero Therapeutics Inc.10-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateSpero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero's licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026 Spero estimates cash and cash equivalents as of December 31, 2025 are sufficient to fund current operations into 2028 CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarte
- PRSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call. About Spero TherapeuticsSpero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare di
- INSIDEROfficer Rajavelu Esther sold $207,484 worth of shares (87,917 units at $2.36), decreasing direct ownership by 8% to 1,012,091 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERChief Operating Officer Keutzer Timothy sold $44,019 worth of shares (18,652 units at $2.36), decreasing direct ownership by 2% to 742,506 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDERChief Operating Officer Keutzer Timothy was granted 68,000 shares and sold $101,175 worth of shares (46,586 units at $2.17), increasing direct ownership by 3% to 761,158 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- INSIDEROfficer Rajavelu Esther was granted 249,000 shares and sold $40,572 worth of shares (18,442 units at $2.20), increasing direct ownership by 27% to 1,100,008 units (SEC Form 4)4 - Spero Therapeutics, Inc. (0001701108) (Issuer)
- SECSEC Form 8-K filed by Spero Therapeutics Inc.8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- SECSEC Form 8-K filed by Spero Therapeutics Inc.8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
- PRSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisCAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026. The NDA res
- PRSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to Spero's new employee in accordance with Nasdaq Listing Rule 5635(c)(4).
- SECSpero Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Spero Therapeutics, Inc. (0001701108) (Filer)
SPRO FAQ
7 questionsWhat does Spero Therapeutics Inc. do?
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary...Where does SPRO stock trade?
Spero Therapeutics Inc. (SPRO) is listed on NASDAQ.What sector and industry is SPRO in?
Spero Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Spero Therapeutics Inc. go public?
Spero Therapeutics Inc. (SPRO) completed its IPO in 2017.What are analysts saying about SPRO?
Spero Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $500.00 price target on 2024-12-20. Recent price targets range from $500.00 to $800.00.What companies are similar to SPRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SPRO side-by-side with any of them on Quantisnow.How can I track SPRO on Quantisnow?
Quantisnow aggregates Spero Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SPRO to receive live email and push alerts on every new disclosure.